Cetuximab Biosimilar, Endotoxin 0.05 EU/mg-远泰生物

提醒成功

QQ登录

微信登录

同意并阅读使用条款和隐私策略

账号密码登录

微信/QQ登录

没有账号？立即注册

搜索

抗体销售咨询健康评估咨询 mRNA-LNP咨询

0731-88388787

首页 > 产品中心 > 产品详情

产品规范
Type	In Vivo - Reseach Grade Antibody
Host	CHO cells
catalog#	B00002.05
Application	Flow cytometry, animal model study
Aliases	Anti-EGFR Chimeric Monoclonal Antibody
Size/Concentration	5mg/20mg
clone	C225
Isotype	Human IgG1
Storage	Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Human EGFR / ErbB-1
Formulation	PBS, pH 7.4

Description
Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations. Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.

Description

Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations. Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.

Cetuximab Biosimilar, Endotoxin 0.05 EU/mg B00002.05

规格：

5mg
20mg

数量：

说明书：

¥7800

~~¥7800~~

加入购物车

立即购买

咨询

ProMab Biotechnologies, Inc.

联系方式

CONTACT

联系电话:

0731-88388787
公司邮箱:

sales@promab.cn
公司地址:

湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼

官方微信

产品中心

Product

技术服务

service

客户留言

message